Kate Therapeutics Debuts With $51 Million Series A to Develop Next-Generation Genetic Medicines to Treat Muscle and Heart Diseases ...Middle East

Series A financing co-led by Westlake Village BioPartners and Versant Ventures Company advancing systemically delivered, skeletal and cardiac muscle targeted, liver de-targeted capsid and cargo technology platforms Initial pipeline addressing myotonic dystrophy type 1 and...

Hence then, the article about kate therapeutics debuts with 51 million series a to develop next generation genetic medicines to treat muscle and heart diseases was published today ( Thursday 08/06/2023 - 11:12 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Kate Therapeutics Debuts With $51 Million Series A to Develop Next-Generation Genetic Medicines to Treat Muscle and Heart Diseases )

Also on site :

• Hundreds of flights delayed at O'Hare after pipe burst at air traffic control tower
• Karamo Brown Skips 'Queer Eye' Interviews and Says He Felt 'Mentally and Emotionally Abused' for Years 
• Humans&, a ‘human-centric’ AI startup founded by Anthropic, xAI, Google alums, raised $480M seed round